十年前,治疗药物只能够提高运动耐量、缓解症状。近年来新的治疗方法能大大改善患者预后,延缓疾病进展,减少住院。肺高压循证诊疗指南着重强调了早期干预和联合治疗的必要性。
爱可泰隆公司中国总经理Sharon Hall女士表示:“爱可泰隆公司致力于解决中国肺动脉高压患者的未满足需求,非常自豪能够为中国肺动脉高压患者带来这种新型口服药物,它有望为患者及其家庭带来新的希望。”
参考资料
1. Data on file. Actelion Pharmaceuticals Ltd, 2018. A
2. McLaughlin VV, et al. Circulation 2009a;119(16):2250-2294.
3.Flattery MP, Pinson JM, Savage L, Salyer J. Living with pulmonary artery hypertension: patients' experiences. Heart Lung 2005; 34(2): 99-107.
4. McDonough A, Matura LA, Carroll DL. Symptom experience of pulmonary arterial hypertension patients. Clin Nurs Res 2011; 20(2): 120-134.
5. Péloquin J, Robichaud-Ekstrand S, Pepin J. Quality of life perception by women suffering from stage III or IV primary pulmonary hypertension and receiving prostacyclin treatment. Can J Nurs Res 1998; 30(1): 113-136.
6. Rubin LJ. Chest. 2004;126:7S-10S.
7. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2009b; 30(20): 2493- 2537.
8. 12 Guillevin L, Armstrong I, Aldrighetti R, Howard LS, Ryftenius H, Fischer A, Lombardi S, Studer S, Ferrari P. Un derstanding the impact of pulmonary arterial hypertension on patients' and carers' lives. Eur Respir Rev 2013; 22(130): 535-542.
9. Selexipag Tablets Package Insert in China.
10. Chinese guidelines for the diagnosis and treatment of pulmonary hypertension 2018. Chin J Cardiol,December 2018, Vol. 46, No. 12.
11. Sitbon O, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2015 Dec 24;373(26):2522-33.
12. SitbonO,et al. Beyond a single pathway: combination therapy in pulmonary arterial hypertension.Eur Respir Rev. 2016 Dec;25(142)408-417.
13. Coghlan JG, et al. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs 2018;18(1):37-47.